Dana-Farber Cancer Institute | Strategic Alliance Partners

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer. 

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

A computer platform developed at Dana-Farber Cancer Institute makes the matching process for clinical trials for patients with genomic alterations both easier and faster.

Dana-Farber Cancer Institute, one of the world’s leading cancer research and treatment centers, has partnered with the Parker Institute for Cancer Immunotherapy, the leading network of immuno-oncology expertise in the world, as a member of the PICI Network with a goal to better understand the tumor microenvironment across cancer types and translate these basic discoveries to the clinic as impactful cancer immunotherapies.

Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.

TAC01-HER2 demonstrated early signals of clinical activity with a tolerable safety profile in patients with HER2-overexpressed solid tumors.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Belzutifan plus cabozantanib sustained antitumor activity in patients with advanced clear cell renal cell carcinoma who previously received immunotherapy.

The triplet regimen of cabozantinib plus standard-of-care nivolumab and ipilimumab reduced the risk of disease progression or death by 27% vs placebo in patients with advanced renal cell carcinoma.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.

Drs Bekaii-Saab, George, and von Mehren discuss patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating DCC-3116 in patients with RAS or RAF–mutated solid tumors, and how vimseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.

Matthew P. Goetz, MD, discusses overall survival data with ribociclib and abemaciclib in estrogen receptor–positive, HER2-negative disease; the role of adjuvant pembrolizumab in patients with triple-negative breast cancer; and the efficacy of PARP inhibitors in earlier settings. 

An online tool developed by researchers and physicians at Dana-Farber Cancer Institute can accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, a new study shows.

Jacqueline S. Garcia, MD, discusses the role of ruxolitinib (Jakafi) in myelofibrosis.

Toni Choueiri, MD, discusses the future examination of adjuvant pembrolizumab in renal cell carcinoma.

Dana-Farber Brigham Cancer Center opened a new facility in Foxborough, MA, which provides world-class cancer care to patients in southern Massachusetts and Rhode Island.

Christine Ryan, MD, discusses the objectives for investigating different sequencing options for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr Berchuck discusses the effects of treatment intensification with darolutamide in metastatic hormone-sensitive prostate cancer, the significance of the approval of darolutamide plus docetaxel and androgen deprivation therapy, and questions left unanswered by the pivotal ARASENS study.

Jacob Berchuck, MD, discusses the effect of the approval of darolutamide tablets on the standard of care for patients with metastatic hormone sensitive prostate cancer.

Avelumab plus talazoparib showcased a favorable toxicity profile and overall modest activity in patients with mismatch repair–proficient endometrial cancer; however, immunogenomic profiling revealed a certain subset who might derive benefit from the doublet, warranting further investigation.

Christine Ryan, MD, discussed the evaluation of safety and efficacy of ibrutinib plus obinutuzumab in patients with relapsed/refractory CLL in the trial and how the results could result in another treatment option for patients with relapsed/refractory CLL.

During the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.

Christine Ryan, MD, discusses the investigation of ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Toni Choueiri, MD, discusses the use of adjuvant pembrolizumab in renal cell carcinoma.

Toni K. Choueiri, MD, explains significant findings from the long-term efficacy analysis of the KEYNOTE-564 study and highlights the significance of these data for the field of RCC.

Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.

Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.

Findings from a phase 1b trial showed that the addition of obinutuzumab to ibrutinib produced a complete response rate that compared favorably with what has historically been observed with ibrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

Dr Tarantino discusses practice-changing findings in breast cancer and emphasizes the ways in which positive study data can improve the breast cancer treatment paradigm going forward.